Clinical trials
Completed Pain trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
106 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 7 |
| 2012 | 5 |
| 2013 | 7 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 9 |
| 2023 | 14 |
| 2024 | 6 |
| 2025 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 106 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Xianwei Zhang | 5 |
| Air Force Military Medical University, China | 4 |
| Jiangsu HengRui Medicine Co., Ltd. | 4 |
| Shijiazhuang Yiling Pharmaceutical Co. Ltd | 4 |
| The University of Hong Kong | 4 |
| Chinese University of Hong Kong | 3 |
| Mundipharma (China) Pharmaceutical Co. Ltd | 3 |
| Peking University People's Hospital | 3 |
| Sun Yat-sen University | 3 |
| Tianjin Medical University General Hospital | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pain | 106 |
| Postoperative Pain | 12 |
| Agnosia | 4 |
| Cancer Pain | 4 |
| Osteoarthritis, Knee | 4 |
| Neuralgia | 3 |
| Adenoma | 2 |
| Anxiety Disorders | 2 |
| Carcinoma, Hepatocellular | 2 |
| Chronic Pain | 2 |
Trials
Showing 1 to 25 of 106. Each trial links to its page on Pharma Observatory.
6 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.